Therapeutic potential of CD20 x CD3 bispecific antibodies

Clin­i­cal-stage neu­ro­science biotech Rap­port Ther­a­peu­tics will seek about $122 mil­lion in net pro­ceeds from its ini­tial pub­lic of­fer­ing, ac­cord­ing to new se­cu­ri­ties pa­per­work out­lin­ing its

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes